GYS1 oligonucleotide antisense therapy (Ionis Pharmaceuticals/NIH)

N/A

Report date: 2025/03/20 16:13:22
NME

Base Information

Drug NameGYS1 oligonucleotide antisense therapy (Ionis Pharmaceuticals/NIH)
Drug Alias NameASO GYS1 (Ionis Pharmaceuticals/NIH)antisense oligonucleotide targeting glycogen synthase (Ionis pharmaceuticals/National institutes of health)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionGlycogen synthase 1 inhibitors
TargetsGlycogen synthase 1
Therapy Area/IndicationsGlycogen Storage Disease Type II
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIonis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Institutes Of HealthIonis Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsGlycogen Storage Disease Type II
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A